share_log

EF Hutton Initiates Coverage On Lantern Pharma With Buy Rating, Announces Price Target of $11

EF Hutton Initiates Coverage On Lantern Pharma With Buy Rating, Announces Price Target of $11

EF Hutton以买入评级启动对Lantern Pharma的报道,宣布目标股价为11美元
Benzinga Real-time News ·  2022/11/01 16:56

EF Hutton analyst Michael King initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $11.

EF Hutton分析师迈克尔·金以买入评级开始对Lantern Pharma(纳斯达克股票代码:LTRN)进行报道,并宣布目标股价为11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发